AlzeCure Pharma presents new NeuroRestore ACD856 data at AD/PD 2024, showing biased PAM function in Alzheimer's treatment without affecting pain signaling.
AlzeCure Pharma has presented new preclinical data on NeuroRestore ACD856, its lead clinical drug candidate, at the Alzheimer's conference AD/PD 2024. The data demonstrates that ACD856, which is focused on Alzheimer's disease, functions as a biased PAM (positive allosteric modulator) and enhances neurite outgrowth without affecting pain signaling. The presentation is now available on AlzeCure's website.
March 07, 2024
4 Articles